Lilly Avoids Strattera Risk Management Program; QTc Key Concern In Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly’s response to an "approvable" letter for Strattera allowed the company to avoid a label requirement to test for poor metabolizers of the drug, as well as a related warning on QTc prolongation, review documents indicate.